Propel Bio Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Propel Bio Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-146,381	Closed	-$423K	–	18
2025 Q2	$423K	Hold	146,381	–	–	0.51%	14
2025 Q1	$423K	Hold	146,381	–	–	0.49%	17
2024 Q4	$765K	Hold	146,381	–	–	0.76%	16
2024 Q3	$1.24M	Hold	146,381	–	–	0.72%	16
2024 Q2	$1.85M	Hold	146,381	–	–	1.2%	16
2024 Q1	$732K	Hold	146,381	–	–	0.43%	24
2023 Q4	$986K	Buy	+146,381	New	+$1.29M	0.82%	25

Propel Bio Management's EIGR Position: Q3 2025 in Review

Propel Bio Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2025, closing a stake of 146,381 shares — an estimated $423K sold.

Propel Bio Management first reported a position in EIGR in Q4 2023 and held it in 7 quarters. The position peaked at $1.85M in Q2 2024. 0 funds tracked by Wall St. Rank hold EIGR as of Q3 2025.

Propel Bio Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2025 after selling out during the quarter.
Propel Bio Management sold 146,381 Eiger BioPharmaceuticals, Inc. shares in Q3 2025, an estimated $423K.
Propel Bio Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2023 and held it in 7 quarters.
Propel Bio Management's Eiger BioPharmaceuticals, Inc. position peaked at $1.85M in Q2 2024.
0 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2025.

Based on Propel Bio Management's 13F filing for Q3 2025, filed 12 Nov 2025.